



## Recent Advances in Pharmacology of Pulmonary Hypertension

Guest Editor:

**Dr. Masashi Tawa**

Faculty of Pharmacy, Osaka  
Medical and Pharmaceutical  
University, Takatsuki, Japan

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editor

Dear Colleagues,

Pulmonary hypertension (PH) is a life-threatening disease caused by the narrowing or blockage of pulmonary vessels. High blood pressure in the pulmonary circulation strains the right side of the heart, leading to right heart failure—a major cause of death for patients with PH. With the development of new drugs, the prognosis of PH has been improving. However, it is still poor and survival is too short; more than 30% of patients die within 5 years of diagnosis. Therefore, advancements in the treatment of PH are needed to improve patient prognosis. This Special Issue has the aim to deepen and broaden our understanding of the pharmacological sciences in the field of PH to develop better therapeutic strategies. Submissions regarding new drug targets, molecular mechanisms of drug action, and novel approaches to therapeutics, including original papers and reviews, are of particular interest.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)